BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Neuroimmunology discovery has continued to expand over the pas
 t year\, with emerging and continued biology and target investigation aga
 inst TREM2\, RIPK1\, ferroptosis\, NLRP3\, LRRK2\, and beyond. However\, 
 there are still significant translational barriers to overcome to see cli
 nical success of neuroinflammatory modulators and tackle the huge unmet p
 atient need in neurology.\n\nCharacterizing and harnessing functions and 
 interactions of microglia\, astrocytes\, oligodendrocytes\, and infiltrat
 ing adaptive immune cells are key to discovering and developing therapies
  to treat underlying neuroinflammation in Alzheimer's\, Parkinson's\, mul
 tiple sclerosis\, and beyond.\n\nJoin 100+ biopharma experts from Alector
 \, Lundbeck\, Vigil Neuroscience\, Biogen\, BMS\, Muna Therapeutics\, Pip
 eline Therapeutics\, PTC Therapeutics\, and more\, breaking down novel gl
 ial biology and neuroinflammatory target investigation\, adaptive immunit
 y contributions\, state of the art microglial iPSCs\, humanized rodent mo
 dels\, neuroinflammatory biomarkers\, and early clinical learnings to opt
 imize neuroimmunology translation and develop transformative therapeutics
  for neurological disorders.\n\n&nbsp\;\n\nDate and Time: On Monday March
  25\, 2024 at 7:30 am to Wednesday March 27\, 2024 at 5:30 pm\n
DTEND:20240327T173000
DTSTAMP:20260512T223116Z
DTSTART:20240325T073000
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, Massachusetts
 \, 02116\,
SEQUENCE:0
SUMMARY:Neuroimmunology discovery has continued to expand over the past ye
 ar\, with emerging and continued biology and target investigation against
  TREM2\, R...
UID:f52eafa4-d4d6-43eb-bcaf-9a60dc685bb6
END:VEVENT
END:VCALENDAR